| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5603969 | Indian Heart Journal | 2017 | 5 Pages |
Abstract
The THRIVE study demonstrated that use of EES yielded a rate for 2 years of major adverse cardiac events comparable to the randomized controlled trial of EES in the SPIRIT trials. This result supports the efficacy and safety of XIENCETM V everolimus eluting for daily interventional cardiology practice.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Songsak Kiatchoosakun, Pavit Pienvichit, Srun Kuanprasert, Navin Suraphakdee, Arintaya Phromminikul,